Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NMS 03597812

Next Previous
Search
Drug Profile

NMS 03597812

Alternative Names: NMS-03597812; NMS-812

Latest Information Update: 03 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EIF-2 kinase inhibitors; EIF2AK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 28 Aug 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06549790)
  • 24 Jun 2024 Nerviano Medical Sciences plans the phase Ia/Ib PERKA-812-003 trial for Acute myeloid leukemia (Second-line therapy or greater) (NCT06549790)
  • 24 Jun 2024 NMS 03597812 is available for licensing as of 24 Jun 2024. http://www.nmsgroup.it

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top